Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

BBIO
BridgeBio Pharma, Inc. Common Stock
stock NASDAQ

At Close
Jul 31, 2026 3:59:57 PM EDT
80.10USD-2.490%(-2.04)2,132,622
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 30, 2026 9:27:30 AM EDT
79.00USD-3.823%(-3.14)0
After-hours
Jul 31, 2026 4:00:30 PM EDT
80.09USD-0.006%(-0.01)307,167
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
07:38AM EST  BridgeBio Pharma Announces Dosing Of First Patient In Phase 1/2 Trial Of Investigational Gene Therapy For Congenital Adrenal Hyperplasia   Benzinga
07:30AM EST  -If successful, BridgeBios investigational gene therapy BBP-631 would be the first therapy for CAH to restore the bodys hormone and steroid balance by enabling people with CAH to make their own cortisol and aldosterone   GlobeNewswire Inc
Jan 25, 2022
09:03AM EST  Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments   PR Newswire
Jan 23, 2022
01:58PM EST  Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (BridgeBio or the Company) (NASDAQ:BBIO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Jan 13, 2022
11:45AM EST  BridgeBio Announces Clinical Collaboration With Amgen To Study BBP-398   Benzinga
09:54AM EST  Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (BridgeBio or the Company) (NASDAQ:BBIO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
07:30AM EST  - First clinical combination study of BBP-398 and LUMAKRAS set to evaluate safety and preliminary efficacy in solid tumors with the KRAS G12C mutation   GlobeNewswire Inc
Jan 4, 2022
05:10AM EST  BridgeBio Pharma Director James C Momtazee Reported Purchase of 80,000 Shares @ Avg Price of $14.50/Share in Form 4 Filing on Monday   Benzinga
Jan 2, 2022
03:30PM EST  The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week   Benzinga
Dec 28, 2021
06:49PM EST  Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (BridgeBio or the Company) (NASDAQ:BBIO). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
10:47AM EST  Where BridgeBio Pharma Stands With Analysts   Benzinga
08:23AM EST  10 Biggest Price Target Changes For Tuesday   Benzinga
07:42AM EST  HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Lowers Price Target to $24   Benzinga
04:32AM EST  SVB Leerink Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $24   Benzinga
Dec 27, 2021
02:57PM EST  Mid-Afternoon Market Update: Dow Surges Over 200 Points; Microbot Medical Shares Spike Higher   Benzinga
12:29PM EST  Mizuho Cuts BridgeBio Pharma Price Target From $86 To $25   Benzinga
12:23PM EST  Mid-Day Market Update: Nasdaq Rises 1%; BridgeBio Pharma Shares Plunge   Benzinga
10:20AM EST  Mid-Morning Market Update: Markets Open Higher; News Corp To Buy Base Chemicals   Benzinga
08:28AM EST  Benzinga Pro's Top 5 Stocks To Watch For Monday, Dec. 27, 2021: JD, MBOT, SOPA, BBIO, ACVT   Benzinga
07:24AM EST  BridgeBio Pharma: ATTRibute-CM Study Fails To Meet Primary   RTTNews
07:15AM EST  BridgeBio Pharma Says ATTRibute-CM Did Not Meet Primary Endpoint At Month 12   RTTNews
07:01AM EST  BridgeBio Pharma Reports Month 12 Results From Phase 3 ATTRibute-CM Study Did Not Meet Its Primary Endpoint   Benzinga
07:00AM EST  - ATTRibute-CM did not meet its primary endpoint at Month 12. Mean observed six-minute walk distance (6MWD) decline for the acoramidis and placebo arms were 9 meters and 7 meters, respectively. Both declines are similar to healthy elderly adults and less than prior untreated ATTR-CM cohorts   GlobeNewswire Inc
Dec 26, 2021
09:53AM EST  The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year   Benzinga
Dec 10, 2021
07:38AM EST  BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
07:30AM EST  BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing   GlobeNewswire Inc
Nov 19, 2021
07:30AM EST  BridgeBio Pharma, Helsinn Report Strategic Collab To Co Develop, Co Commercialize BridgeBio's Novel GPX4 Inhibitor Cancer Tumor Types   Benzinga
07:30AM EST  - The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs   GlobeNewswire Inc
04:53AM EST  SVB Leerink Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $66   Benzinga
Nov 18, 2021
02:06PM EST  BridgeBio Pharma Secures Debt Financing Of $750M   Benzinga
07:41AM EST  BridgeBio Pharma Executes Definitive Credit Facility Deal With A Syndicate Of Lenders For Up To $750.0 Mln In Financing   RTTNews
07:34AM EST  BridgeBio Pharma Reports Secured Up To $750M In Non-Dilutive Debt Financing   Benzinga
07:30AM EST  -Innovative financing facility and existing cash balance gives BridgeBio access to over $1.2 billion, which is expected to fully fund the Companys 30+ genetic disease and cancer pipeline programs into 2024   GlobeNewswire Inc
Nov 4, 2021
08:35AM EDT  BridgeBio Pharma Q3 EPS $(1.06) Down From $(0.98) YoY, Sales $2.34M Down From $8.13M YoY   Benzinga
07:31AM EDT  BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business   PR Newswire
Nov 3, 2021
09:16AM EDT  BridgeBio Pharma Announces Dosing Of First Patient In Phase 1/2 Trial Of Investigational Gene Therapy For Canavan Disease   Benzinga
07:31AM EDT  BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of   PR Newswire
Oct 29, 2021
07:36AM EDT  BridgeBio Pharma Reports Collabs With Columbia University, Mount Sinai To Develop Potential Therapies For Genetic Diseases, Cancers   Benzinga
07:33AM EDT  BridgeBio Pharma Collaborates With Columbia University To Develop Therapies For Genetic Diseases And Cancers   RTTNews
07:31AM EDT  BridgeBio Pharma Announces Collaborations with Columbia University and Mount   PR Newswire
Oct 25, 2021
07:31AM EDT  BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and   PR Newswire
06:35AM EDT  HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $88   Benzinga
Oct 12, 2021
07:31AM EDT  Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers   PR Newswire
Oct 7, 2021
09:21AM EDT  BridgeBio Announces Publication Of Data For Best-in-Class SHP2 Inhibitor Designed For Treatment Of Resistant Cancer   RTTNews
09:05AM EDT  BridgeBio Pharma Announces First Publication Of Preclinical Data For Potentially Best-In-Class SHP2 Inhibitor Designed For Treatment Of Resistant Cancer, Showing Response In Established Non-small Cell Lung Cancer Models   Benzinga
09:05AM EDT  Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-small Cell Lung Cancer Models   PR Newswire
Oct 6, 2021
07:31AM EDT  BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021   PR Newswire
Oct 4, 2021
09:56AM EDT  UPDATE: SVB Leerink On BridgeBio Price Target Raise: Firm Notes Additional Phase 2 Data Of Encaleret Shows Treatment 'Continues To Be Well-Tolerated With No Serious Adverse Events'; Sees Co. Plans To Meet With FDA By YE21 With Phase 3 Initiation In FY22   Benzinga
08:31AM EDT  10 Biggest Price Target Changes For Monday   Benzinga
06:16AM EDT  SVB Leerink Maintains Outperform on BridgeBio Pharma, Raises Price Target to $68   Benzinga
Oct 1, 2021
05:00PM EDT  Dominant Hypocalcemia Type 1 (ADH1) Demonstrating Blood and Urine Calcium Normalization in Trial Participants   PR Newswire
Sep 15, 2021
07:45AM EDT  BridgeBio Pharma Inc. (BBIO) said Wednesday that the U.S. Food and Drug Administration granted Fast Track designation for the investigation of BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type 2i or LGMD2i.   RTTNews
07:33AM EDT  BridgeBio Receives FDA Fast Track Designation For Therapy For Treatment Of Limb-girdle Muscular Dystrophy Type 2i   RTTNews
07:32AM EDT  BridgeBio Pharma Receives FDA Fast Track Designation For Investigational Therapy For The Treatment Of Limb-girdle Muscular Dystrophy Type 2i   Benzinga
07:31AM EDT  Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)   PR Newswire
Sep 10, 2021
07:36PM EDT  B of A Securities Upgrades BridgeBio Pharma to Buy, Announces $75 Price Target   Benzinga
Sep 8, 2021
05:01PM EDT  BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)   PR Newswire
Aug 25, 2021
07:03AM EDT  BridgeBio Pharma And LianBio Announce First Patient Treated In Phase 2a Trial Of Infigratinib In Patients With Gastric Cancer And Other Advanced Solid Tumors   Benzinga
Aug 18, 2021
07:31AM EDT  BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan,   PR Newswire
Aug 6, 2021
05:56AM EDT  SVB Leerink Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $66   Benzinga
Aug 5, 2021
07:51AM EDT  BridgeBio Pharma Q2 EPS $(0.66) Up From $(1.03) YoY   Benzinga
07:50AM EDT  BridgeBio Pharma Q2 Loss/shr Narrows $0.66 From $1.03 Last Year   RTTNews
07:31AM EDT  BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and   PR Newswire
Aug 4, 2021
07:02PM EDT  BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)   PR Newswire
Jul 27, 2021
11:13AM EDT  BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb To Study BBP-398 In Combination With OPDIVO In Advanced Solid Tumors With KRAS Mutations   Benzinga
Jul 12, 2021
04:31PM EDT  BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)   PR Newswire
Jul 8, 2021
07:33AM EDT  BridgeBio Pharma Announces Collaborations With Three Academic Research Institutions   RTTNews
07:31AM EDT  BridgeBio Pharma Announces Collaborations with Three Academic Research   PR Newswire
Jun 28, 2021
07:10PM EDT  BIOMEA Fusion Strengthens its Executive Team with Appointment of   GlobeNewswire Inc
Jun 14, 2021
04:35PM EDT  BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing   GlobeNewswire Inc
Jun 2, 2021
10:38AM EDT  Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates   Benzinga
Jun 1, 2021
08:02AM EDT  FDA Approves BridgeBio Pharma's FGFR2 Inhibitor for Bile Duct Cancer   Benzinga
07:30AM EDT  BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret   GlobeNewswire Inc
07:04AM EDT  BridgeBio Affiliate QED Therapeutics And Helsinn Group Announce FDA Approval Of TRUSELTIQ For Patients With Cholangiocarcinoma   Benzinga
07:00AM EDT  BridgeBio Pharma's Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ(tm) (infigratinib) for Patients with Cholangiocarcinoma   Business Wire
May 28, 2021
02:32PM EDT  BridgeBio Pharma's Affiliate QED Therapeutics And Partner Helsinn Group Announce FDA Approval Of TRUSELTIQ For Patients With Cholangiocarcinoma   Benzinga
02:30PM EDT  Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement   GlobeNewswire Inc
May 21, 2021
10:08AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021   Benzinga
06:30AM EDT  UBS Initiates Coverage On BridgeBio Pharma with Buy Rating, Announces Price Target of $80   Benzinga
May 14, 2021
04:30PM EDT  BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing   GlobeNewswire Inc
07:59AM EDT  BridgeBio Pharma Inc. (BBIO) said that the U.S. Food and Drug Administration granted Fast Track designation to BBP-631, an investigational adeno-associated virus 5 gene therapy designed for the treatment of congenital adrenal hyperplasia.   RTTNews
07:42AM EDT  BridgeBio Pharma Says FDA Granted Fast Track Designation To BBP-631   RTTNews
07:33AM EDT  BridgeBio Pharma Receives FDA Fast Track Designation For Investigational Gene Therapy For Congenital Adrenal Hyperplasia   Benzinga
07:30AM EDT  BridgeBio Pharma Receives FDA Fast Track Designation for   GlobeNewswire Inc
May 7, 2021
08:05AM EDT  Goldman Sachs Maintains Buy on BridgeBio Pharma, Lowers Price Target to $80   Benzinga
May 6, 2021
08:05AM EDT  BridgeBio Pharma Q1 EPS $(1.18) Down From $(0.78) YoY   Benzinga
07:30AM EDT  Received U.S. Food and Drug Administration (FDA) approval for NULIBRY (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A   GlobeNewswire Inc
Apr 20, 2021
07:49AM EDT  bluebird bio Says Investigator Has Concluded Reported Case Of MDS In LentiGlobin Study Is Not MDS And Has Revised Diagnosis To Transfusion-Dependent Anemia   Benzinga
Apr 19, 2021
09:14AM EDT  Biologics By McKesson Selected By BridgeBio's Origin Biosciences As Exclusive Specialty Pharmacy Provider For NULIBRYTM   Benzinga
Apr 13, 2021
07:45AM EDT  BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate research in genetically driven conditions into potential therapeutic applications for patients, with a focus on oncology and neurology.   GlobeNewswire Inc
07:44AM EDT  BridgeBio Pharma Shares Quiet Premarket After Co. Announced Multiple Research Collaborations For Genetically Driven Diseases   Benzinga
07:42AM EDT  BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patients with genetically driven conditions and cancers.   GlobeNewswire Inc
07:40AM EDT  BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Roswell Park Comprehensive Cancer Center to advance the development of investigational therapeutics for patients with genetically driven cancers.   GlobeNewswire Inc
07:38AM EDT  BridgeBio Pharma And Oregon Health & Science University To work To Advance Potential Therapies For Genetically Driven Diseases   Benzinga
07:37AM EDT  BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Oregon Health & Science University (OHSU) in Portland, Oregon, to advance research and the development of investigational medicines for patients with genetically driven conditions.   GlobeNewswire Inc
07:35AM EDT  BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center today announced a collaboration to translate research in genetically driven diseases and cancers into potential treatments for patients.   GlobeNewswire Inc
07:32AM EDT  BridgeBio Pharma, Inc. (NASDAQ: BBIO) and the Canadian Glycomics Network (GlycoNet), a pan-Canadian Network of Centres of Excellence, today announced a collaboration to translate scientific research in glycomics into potential treatments for patients with genetic diseases.   GlobeNewswire Inc
07:30AM EDT  BridgeBio Pharma, Inc. (NASDAQ: BBIO), and Brown University today announced a formal collaboration to advance research in genetically driven neurological disorders into potential life-changing medicines for patients.   GlobeNewswire Inc
Apr 6, 2021
04:30PM EDT  BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing   GlobeNewswire Inc
Mar 31, 2021
11:46AM EDT  BridgeBio Locks $2B Infigratinib Global Partnership For Oncology Indications   Benzinga
07:33AM EDT  BridgeBio Pharma's Affiliate QED Therapeutics And Helsinn Group Announce Strategic Collaboration Co Co-Develop And Commercialize Infigratinib In Oncology   Benzinga
07:30AM EDT  - BridgeBio, through its affiliate QED (BridgeBio), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than skeletal dysplasia indications in the U.S. and equally share profits   GlobeNewswire Inc
Mar 23, 2021
05:39AM EDT  SVB Leerink Maintains Outperform on BridgeBio Pharma, Raises Price Target to $75   Benzinga
Mar 22, 2021
11:17AM EDT  UPDATE: Goldman On BridgeBio Notes Weekend Data On Enclaret Showed Normalization Of Blood, Urine Calcium Levels By Day 5 Of Treatment   Benzinga
11:16AM EDT  UPDATE: Goldman Highlights Weekend Data Presented At Endo Conference By BridgeBio On Co.'s ADH1 Treatment Candidate, Called Phase 2b Data 'Impressive'   Benzinga
Mar 20, 2021
11:42AM EDT  BridgeBio Pharma Announces Proof-of-Concept Data Of Encaleret In ADH1 At Endocrine Society's 2021 Annual Meeting   RTTNews
11:00AM EDT  Normalization of Blood Calcium and Urine Calcium in 6 of 6 (100%) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Participants Initially Evaluated Over 5 Days Demonstrates Proof-of-Concept   GlobeNewswire Inc
Mar 14, 2021
08:14AM EDT  Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations   Benzinga
Mar 4, 2021
09:35AM EST  Mizuho Maintains Buy on BridgeBio Pharma, Raises Price Target to $86   Benzinga
Mar 2, 2021
04:30PM EST  BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing   GlobeNewswire Inc
Mar 1, 2021
05:17AM EST  BridgeBio Pharma Gets First FDA-Approval For Rare Genetic Metabolic Disorder   Benzinga
Feb 28, 2021
10:12PM EST  BridgeBio Pharma Inc. (BBIO) and affiliate Origin Biosciences Inc. said that the U.S. Food and Drug Administration has approved NULIBRY or fosdenopterin for Injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency or MoCD Type A.   RTTNews
08:00AM EST  Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high infant mortality rate; median overall survival age is about four years   GlobeNewswire Inc
Feb 25, 2021
08:14AM EST  BridgeBio Pharma Q4 EPS $(1.01) Down From $(0.62) YoY, Sales $122.00K Down From $13.82M YoY   Benzinga
07:30AM EST  Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval of Eidos product candidate, acoramidis, a potential best-in-class therapy for patients with amyloidosis cardiomyopathy (ATTR-CM)   GlobeNewswire Inc
Feb 24, 2021
04:01PM EST  BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at   GlobeNewswire Inc
Feb 20, 2021
02:17PM EST  The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More   Benzinga
Feb 19, 2021
01:01PM EST  BridgeBio Pharma's BBP-418 Muscular Dystrophy Study Moves Forward With Patient Dosing   Benzinga
07:34AM EST  BridgeBio And ML Bio Solutions Dose First Patient In Phase 2 Trial Of BBP-418 In Limb Girdle Muscular Dystrophy Type 2i   RTTNews
07:31AM EST  BridgeBio Pharma And Affiliate ML Bio Solutions Announce Dosing Of First Patient In Phase 2 Trial Of BBP-418 In Limb Girdle Muscular Dystrophy Type 2i   Benzinga
07:30AM EST  BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of   GlobeNewswire Inc
Feb 12, 2021
09:57AM EST  BridgeBio Pharma shares were trading lower after the company reported a 3 million share common stock offering via selling shareholders.   Benzinga
08:01AM EST  BridgeBio Announces Pricing Of Secondary Offering Of 3M Shares Of Common Stock At $62.50/Share   Benzinga
08:00AM EST  BridgeBio Pharma, Inc. Announces Pricing of Secondary Offering of   GlobeNewswire Inc
Feb 11, 2021
04:26PM EST  BridgeBio Pharma Reports 3M Share Common Stock Offering Via Selling Shareholders   Benzinga
04:10PM EST  BridgeBio Pharma, Inc. Announces Launch of Secondary Offering of   GlobeNewswire Inc
Feb 10, 2021
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
08:00AM EST  Goldman Sachs Reinstates Buy on BridgeBio Pharma, Announces $83 Price Target   Benzinga
Feb 5, 2021
04:30PM EST  BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing   GlobeNewswire Inc
Feb 2, 2021
07:41AM EST  BridgeBio Pharma Reports Dosing Of First Patient In Phase 1/2 Trial Of BBP-681 For Venous, Lymphatic, Venolymphatic Malformations   Benzinga
07:40AM EST  BridgeBio Pharma, Affiliate Venthera Announce Dosing Of First Patient In Phase 1/2 Clinical Trial Of BBP-681 For Venous, Lymphatic, Venolymphatic Malformations   Benzinga
07:30AM EST  -- First-in-human Phase 1/2 trial in patients with venous malformations (VMs), lymphatic malformations (LMs), and venolymphatic malformations (VLMs) associated with PIK3CA or TEK mutations -- Clinical trial enrolling patients across multiple sites in the United States   GlobeNewswire Inc
Jan 26, 2021
08:43AM EST  BridgeBio Pharma Shares Move Higher; Co Announces Completion Of Merger With Eidos Therapeutics   Benzinga
08:30AM EST  BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (Eidos) (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own. The transaction was overwhelmingly approved by BridgeBio and Eidos stockholders.   GlobeNewswire Inc
12:08AM EST  BridgeBio Pharma Prices $650 Mln Of 2.25% Convertible Notes Due 2029 In A Private Offering To Institutional Buyers   RTTNews
Jan 25, 2021
11:04PM EST  BridgeBio Pharma, Inc. Prices Upsized Offering of $650 Million   GlobeNewswire Inc
07:12AM EST  BridgeBio Pharma Announces Proposed Offering Of $400 Mln Of Convertible Senior Notes Due 2029   RTTNews
07:00AM EST  BridgeBio Pharma, Inc. Announces Proposed Offering of $400 Million   GlobeNewswire Inc
Jan 19, 2021
04:04PM EST  Stockholders of BridgeBio Pharma and Eidos Therapeutics Approve BridgeBio Pharma Acquisition of Eidos Therapeutics   Benzinga
04:01PM EST  Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc   GlobeNewswire Inc
Jan 13, 2021
04:32PM EST  BridgeBio Pharma And E Therapeutics Announce That The Acquisition Of Eidos Common Stock Not Held By BridgeBio As Mentioned In Previous Merger Agreement Is Set To Close On January 26th   Benzinga
04:30PM EST  BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce   GlobeNewswire Inc
Jan 11, 2021
06:26AM EST  HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $87   Benzinga
Jan 6, 2021
04:30PM EST  BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing   GlobeNewswire Inc
Jan 5, 2021
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
Jan 4, 2021
11:42AM EST  Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Eidos Therapeutics, Inc. (NASDAQ: EIDX) breached their fiduciary duties or violated the federal securities laws in connection with the companys merger BridgeBio Pharma, Inc. (NASDAQ: BBIO).   GlobeNewswire Inc
07:46AM EST  ISS Recommends BridgeBio Pharma, Eidos Therapeutics Stockholders Vote For Proposed Merger   RTTNews
07:30AM EST  Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio   GlobeNewswire Inc
Dec 29, 2020
08:09AM EST  The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica   Benzinga
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
07:38AM EST  UCSF And BridgeBio Pharma Collaborate To Accelerate Development Of Therapies For Genetic Diseases   RTTNews
07:33AM EST  BridgeBio Reports Collaboration With UC San Francisco To Accelerate Development Of Therapies For Genetic Diseases   Benzinga
07:30AM EST  UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.   GlobeNewswire Inc
Dec 19, 2020
04:11PM EST  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following   PR Newswire
Dec 18, 2020
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
Dec 17, 2020
11:08PM EST  Lifshitz Law Firm, P.C. Announces Investigation of ARA, BBIO, EIDX, CIT, EMIS,   PR Newswire
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 14, 2020
07:23AM EST  'Glaxo Bids $120 a Share for Eidos in Rival Offer' -Bloomberg, From Friday   Benzinga
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 10, 2020
07:55AM EST  10 Biggest Price Target Changes For Thursday   Benzinga
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
06:16AM EST  HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $64   Benzinga
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 7, 2020
08:34AM EST  BridgeBio Pharma And Maze Therapeutics Establish Joint Venture To Advance Precision Medicine To Treat Cardiovascular Disease   Benzinga
08:30AM EST  Contour Therapeutics Brings Together Leaders with Extensive Cardiovascular, Genetics and Drug Development Expertise   GlobeNewswire Inc
Dec 4, 2020
04:30PM EST  BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing   GlobeNewswire Inc
11:46AM EST  Merger Investigations; Investors are Encouraged to Contact the Firm - WORK, WDR, BBIO, UROV, HDS   PR Newswire
08:00AM EST  10 Biggest Price Target Changes For Friday   Benzinga
06:06AM EST  SVB Leerink Maintains Outperform on BridgeBio Pharma, Raises Price Target to $44   Benzinga
Dec 2, 2020
02:39PM EST  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation   GlobeNewswire Inc
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Dec 1, 2020
08:08AM EST  The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit   Benzinga
07:37AM EST  BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma   Benzinga
07:30AM EST  Application accepted under Priority Review designationApplication accepted into Real Time Oncology Review (RTOR) pilot programThis is BridgeBiossecond NDA acceptanceApplication will also be submitted for review in Australia and Canada under Project Orbis   GlobeNewswire Inc
Nov 25, 2020
08:01AM EST  Lifshitz Law Firm, P.C. Announces Investigation of ARA, BBIO, BMCH, BLDR, CIT,   PR Newswire
Nov 13, 2020
07:31AM EST  BridgeBio Pharma, Affiliate Navire Pharma Report Dosing Of First Patient In Phase 1 Trial Of SHP2 Inhibitor BBP-398 For Tumors Driven By RAS, Receptor Tyrosine Kinase Mutations   Benzinga
07:30AM EST  BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of   GlobeNewswire Inc
Nov 9, 2020
06:17PM EST  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigation of   PR Newswire
Nov 6, 2020
08:01AM EST  Holdings, Inc., BMC Stock Holdings, Inc., Callaway Golf Company, Cellular Biomedicine Group, Inc., CIT Group Inc., Eidos Therapeutics, Inc., Watford Holdings Ltd. and Yintech Investment Holdings Limited   PR Newswire
Nov 5, 2020
07:41AM EST  BridgeBio Pharma Q3 EPS $(0.98) Down From $(0.51) YoY, Sales $8.13M Down From $26.74M YoY   Benzinga
07:30AM EST  -Merger agreement executed between BridgeBio and Eidos Therapeutics; Potential to bring BridgeBios clinical and commercial development infrastructure to bear upon Eidos Acoramidis   GlobeNewswire Inc
Nov 4, 2020
04:30PM EST  BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing   GlobeNewswire Inc
Oct 27, 2020
07:51AM EDT  BridgeBio Pharma And Affiliate Phoenix Tissue Repair Announce First Patient Dosing In Phase 2 Trial Of Protein Replacement Therapy For The Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB)   Benzinga
07:30AM EDT  BridgeBio Pharma and Affiliate Phoenix Tissue Repair Announce   GlobeNewswire Inc
Oct 23, 2020
04:44PM EDT  Holdings, Inc., BMC Stock Holdings, Inc., Builders FirstSource, Inc., Cellular Biomedicine Group, Inc., CIT Group Inc., Eidos Therapeutics, Inc., MyoKardia, Inc. Watford Holdings Ltd. and Yintech Investment Holdings Limited   PR Newswire
Oct 21, 2020
07:34AM EDT  BridgeBio Reports Collaboration With University Of Colorado Anschutz Medical Campus To Advance Medicines For Genetically Driven Diseases   Benzinga
07:30AM EDT  BridgeBio Pharma, Inc. (Nasdaq: BBIO) and the University of Colorado Anschutz Medical Campus today announced a collaboration to advance novel research on genetically driven diseases into therapeutic applications for patients.   GlobeNewswire Inc
07:27AM EDT  Salk Institute And BridgeBio Pharma Collaborate To 'Advance Therapies for Genetically Driven Disease'   Benzinga
07:25AM EDT  Salk Institute and BridgeBio Pharma Collaborate to Advance   GlobeNewswire Inc
Oct 15, 2020
12:07PM EDT  Lifshitz Law Firm, P.C. Announces Investigation of American Renal   GlobeNewswire Inc
Oct 12, 2020
06:37AM EDT  HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $53   Benzinga
Oct 5, 2020
09:00PM EDT  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation   GlobeNewswire Inc
01:47PM EDT  Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Eidos Therapeutics, Inc. (NASDAQ: EIDX) breached their fiduciary duties or violated the federal securities laws in connection with the companys merger with BridgeBio Pharma, Inc. (NASDAQ: BBIO).   GlobeNewswire Inc
09:07AM EDT  (EIDX) Alert: Johnson Fistel Investigates Proposed Sale of Eidos Therapeutics;   PR Newswire
08:13AM EDT  BridgeBio Pharma, Inc. (BBIO), a company focused on genetic diseases,announced Monday a definitive agreement to acquire around 36.3% stake in Eidos Therapeutics, Inc. (EIDX), a company focused on transthyretin or TTR amyloidosis or ATTR, that it does not already own. The deal has a value of up to an aggregate maximum of $175 million of cash.   RTTNews
07:10AM EDT  BridgeBio Agrees To Acquire All Outstanding Shares Of Eidos It Does Not Already Own   RTTNews
07:06AM EDT  BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement; Eidos Stockholders Will Have The Right To Receive In The Transaction, At Their Election, Either 1.85 Shares Of Bridgebio Common Stock Or $73.26 In Cash Per Eidos Share In The Transaction, Up To An Aggregate Maximum Of $175M Of Cash   Benzinga
07:06AM EDT  BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement; Eidos Stockholders Will Have The Right To Receive In The Transaction, At Their Election, Either 1.85 Shares Of Bridgebio Common Stock Or $73.26 In Cash Per Eidos Share In The Transaction   Benzinga
07:04AM EDT  BridgeBioto Acquire All Outstanding Shares of Eidos it Does Not Already Own   GlobeNewswire Inc
Sep 29, 2020
07:37AM EDT  BridgeBio Pharma: FDA Accepts NDA For Fosdenopterin For The Treatment Of MoCD Type A   RTTNews
07:31AM EDT  BridgeBio Pharma And Affiliate Origin Biosciences Announces FDA Acceptance Of Its New Drug Application For Fosdenopterin For Treatment Of MoCD Type A   Benzinga
07:30AM EDT  Application accepted under Priority Review designationwithBreakthrough Therapy Designation and Rare Pediatric Disease Designation previously granted   GlobeNewswire Inc
Sep 22, 2020
07:30AM EDT  BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases and cancers with clear genetic drivers, today announced that it will host its first R&D Day on Tuesday, September 29, at 8:30 am E.T.   GlobeNewswire Inc
Sep 21, 2020
07:32AM EDT  BridgeBio Pharma's Calcilytix Therapeutics Initiates Phase 2 Study Of Encaleret For Autosomal Dominant Hypocalcemia Type 1   Benzinga
07:30AM EDT  -- Topline proof-of-concept resultsin ADH1 anticipated in 2021 -- Currently, there are no approved therapies for ADH1   GlobeNewswire Inc
Sep 3, 2020
05:30PM EDT  BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing   GlobeNewswire Inc
Aug 11, 2020
07:43AM EDT  BridgeBio Pharma Q2 EPS $(1.03) Down From $(0.71) YoY; Ended Quarter With $840.9M In Cash And Equivalents   Benzinga
07:41AM EDT  BridgeBio Pharma Announces Collaboration With LianBio; Co. To Receive $26.5M In Near-Term Payments And Up To $505M In Future Milestone Payments   Benzinga
07:40AM EDT  -Initiated four clinical trials, progressed its additional 11 ongoing clinical trials and submitted three INDs to FDA since the beginning of 2020   GlobeNewswire Inc
07:35AM EDT  $26.5 million total near-term payments to BridgeBio, plus participation in long-term value creation of up to $505 million in milestone payments, tiered double-digit royalty payments and an equity interest in LianBio.   GlobeNewswire Inc
Jul 28, 2020
04:52PM EDT  Bridgebio Pharma Files For Common Stock Shelf Of Up To 65.1M Shares By Selling Stockholders   Benzinga
07:30AM EDT  -- Precision medicine study designed to confirm drugs ability to cross blood-brain barrier and hit molecular targets in high-grade glioma patients with FGFR genetic alterations -- Patients with a positive PK response will continue on infigratinib after surgery   GlobeNewswire Inc
Jul 15, 2020
07:39AM EDT  BridgeBio Pharma's QED Therapeutics Doses First Child In Phase 2 Clinical Trial Of Infigratinib In Achondroplasia   RTTNews
07:34AM EDT  BridgeBio Pharma's QED Therapeutics Doses First Child In Phase 2 Clinical Trial Of The Investigational Medicine Infigratinib In Achondroplasia   Benzinga
07:30AM EDT  BridgeBio Pharmas QED Therapeutics Doses First   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC